Ann: MYX signs license agreement for women's health products, page-97

Based on today’s share price, Mayne has a market cap of $330 million. Prior to buying the new suite of drugs we had $320 in the bank (saving approximately 20+ million in interest on our past debt commitments btw). That leaves the value of the company’s assets at just $10 million.
Considering we gave up 10% of the company’s stock ($33million on todays price) plus US$20mil in cash for nextellis then spent at least that again marketing it puts nextellis alone at a AUD cost of approximately $120 million.
if the market has it correct, nextellis plus all our other assets, including plant and property at Salisbury and the $9mill of upgrades that just went in there, are only valued at AUD$10mil?
if that is true then management is truly woeful but the balance sheet looks stable to me. Would be nice in this uncertain environment for the CEO to provide more info on what our new balance sheet looks like, how much goodwill we have attached to each product and the cost savings we will get in having less debt.

just my 2 cents